/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Biohaven Ltd share price today is $9.91, up -5.26%. The stock opened at $10.37 against the previous close of $10.46, with an intraday high of $10.71 and low of $9.89.

style

pb-0

Biohaven Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$9.91 -0.0526(-5.26%) BHVN at 13 Mar 2026 12:12 PM Biotechnology

Lowest Today 9.89

Highest Today 10.71

Today’s Open 10.37

Prev. Close 10.46

52 Week High 31.18

52 Week Low 7.48

Day’s Range: Low 9.89 High 10.71

52-Week Range: Low 7.48 High 31.18

Biohaven Ltd Institutional Holdings

Biohaven Ltd Market Status

Strong Buy: 11

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Biohaven Ltd Fundamentals

Market Cap 1573.36 M

PB Ratio 29.6663

PE Ratio 0.0

Enterprise Value 1538.84 M

Total Assets 451.45 M

Volume 1693051

Biohaven Ltd Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:462509000 462.5M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:-3369000 -3.4M, FY22:null 0.0M, FY21:370845000 370.8M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-408168000 -408.2M, FY22:-570279000 -570.3M, FY21:-213796000 -213.8M, FY20:-118668000 -118.7M, FY19:-528805000 -528.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1105000 -1.1M, Q2/2025:null 0.0M, Q1/2025:-1014999 -1.0M, Q3/2024:null 0.0M, Q2/2024:-977000 -1.0M

Quarterly Net worth Q3/2025:-173443000 -173.4M, Q2/2025:-198147000 -198.1M, Q1/2025:-221677000 -221.7M, Q3/2024:-160304000 -160.3M, Q2/2024:-319771000 -319.8M

About Biohaven Ltd & investment objective

Company Information Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Organisation Biotechnology

Employees 274

Industry Biotechnology

CEO Dr. Vladimir Coric M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*